MeiraGTx–Bank of America: investor conference, 201905 supply service MeiraGTx presents at BoAML Global Healthcare Conference in Las Vegas

	Period	2019-05-15
	Partner, 1st	MeiraGTx Holdings Plc (NASDAQ: MGTX)
	Group	MeiraGTx (Group)
	Partner, 2nd	Bank of America Merrill Lynch (BofA Merrill Lynch, marketing name of Bank of America Corporation)
	Group	Bank of America (BofA) (Group)
	Product	Bank of America Merrill Lynch Global Healthcare Conference 2019 Las Vegas
	Product 2	gene therapy
	Person	Forbes, Alexandria (MeiraGTx 201810 CEO)
	Person 2	Anderson (formerly Broder), Elizabeth (LianBio 202103 VP Communications + IR before MeiraGTx)

MeiraGTx Holdings plc. (5/6/19). "Press Release: MeiraGTx to Present at Bank of America Merrill Lynch Healthcare Conference". London & New York, NY.

MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the BAML Healthcare Conference on Wednesday, May 15, 2019, at 3:55 p.m. PST.

Dr. Forbes will also be participating on the “Gene Therapy” panel at the BAML Healthcare Conference on Wednesday May 15, 2019 at 4:20 p.m. PST.

A live webcast of MeiraGTx’s May 15th presentation and the accompanying presentation materials will be available from the Investors page of the Company’s website at www.investors.meiragtx.com. A replay of the webcast will be available for 30 days following the presentation.

About MeiraGTx

MeiraGTx (NASDAQ:MGTX) is a vertically integrated, clinical stage gene therapy company with five programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring and developing technologies that give depth across both product candidates and indications. MeiraGTx’s initial focus is on three distinct areas of unmet medical need: inherited retinal diseases, neurodegenerative diseases and severe forms of xerostomia and xerophthalmia. Though initially focusing on the eye, central nervous system and salivary gland, MeiraGTx intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.

For more information, please visit www.meiragtx.com.

Contacts

Investors:
MeiraGTx
Elizabeth Broder
(646) 860-7983
Investors@meiragtx.com
or
Media:
W2O pure
Christiana Pascale
(212) 267-6722
cpascale@purecommunications.com